Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial (vol 165, pg 573, 2017)

Nitz Ulrike; Gluz Oleg; Christgen Matthias; Kates Ronald E.; Clemens Michael; Malter Wolfram; Nuding Benno; Aktas Bahriye; Kuemmel Sherko; Reimer Toralf; Stefek Andrea; Lorenz-Salehi Fatemeh; Krabisch Petra; Just Marianne; Augustin Doris; Liedtke Cornelia; Chao Calvin; Shak Steven; Wuerstlein Rachel; Kreipe Hans H.; Harbeck Nadia

首页> 外文期刊>Breast cancer research and treatment. >Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial (vol 165, pg 573, 2017)

【24h】

Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial (vol 165, pg 573, 2017)

机译：减少化疗在临床高风险，基因组低风险的PN0和PN1早期乳腺癌患者中：从前瞻性，随机第3阶段3西德语学习组（WSG）Planb审判的五年数据（Vol 165，PG 573,2017）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Breast cancer research and treatment.》 |2019年第1期|共2页
作者
Nitz Ulrike; Gluz Oleg; Christgen Matthias; Kates Ronald E.; Clemens Michael; Malter Wolfram; Nuding Benno; Aktas Bahriye; Kuemmel Sherko; Reimer Toralf; Stefek Andrea; Lorenz-Salehi Fatemeh; Krabisch Petra; Just Marianne; Augustin Doris; Liedtke Cornelia; Chao Calvin; Shak Steven; Wuerstlein Rachel; Kreipe Hans H.; Harbeck Nadia;
展开▼
作者单位

West German Study Grp Ludwig Weber Str 15 D-41061 Monchengladbach Germany;

West German Study Grp Ludwig Weber Str 15 D-41061 Monchengladbach Germany;

Med Sch Hannover Inst Pathol Carl Neuberg Str 1 D-30625 Hannover Germany;

West German Study Grp Ludwig Weber Str 15 D-41061 Monchengladbach Germany;

Clin Mutterhaus Borromaerinnen Dept Oncol Feldstr 16 D-54290 Trier Germany;

Univ Clin Cologne Breast Ctr Dept Gynecol &

Obstet Kerpener Str 62 D-50937 Cologne Germany;

Evangel Hosp Dept Gynecol &

Obstet Ferrenbergstr 24 D-51465 Bergisch Gladbach Germany;

Univ Clin Essen Dept Gynecol &

Obstet Hufelandstr 55 D-45147 Essen Germany;

Clin Essen Mitte Breast Ctr Henricistr 92 D-45136 Essen Germany;

Clin Suedstadt Dept Gynecol &

Obstet Sudring 81 D-18059 Rostock Germany;

Breast Ctr Altmark Johanniter Clin Stendal Bahnhofstr 24-26 D-39576 Stendal Germany;

Dr Horst Schmidt Clin Dept Gynecol Ludwig Erhard Str 100 D-65199 Wiesbaden Germany;

Klinikum Chemnitz Flemmingstr 2 D-09116 Chemnitz Germany;

Teutoburger Str 60 D-33604 Bielefeld Germany;

Breast Ctr Ostbayern Perlasberger Str 41 D-94469 Deggendorf Germany;

West German Study Grp Ludwig Weber Str 15 D-41061 Monchengladbach Germany;

Genom Hlth Inc Redwood City CA USA;

Genom Hlth Inc Redwood City CA USA;

West German Study Grp Ludwig Weber Str 15 D-41061 Monchengladbach Germany;

Med Sch Hannover Inst Pathol Carl Neuberg Str 1 D-30625 Hannover Germany;

West German Study Grp Ludwig Weber Str 15 D-41061 Monchengladbach Germany;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献

1. Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial (vol 165, pg 573, 2017) [J] . Nitz Ulrike, Gluz Oleg, Christgen Matthias, Breast cancer research and treatment. . 2019,第1期

机译：减少化疗在临床高风险，基因组低风险的PN0和PN1早期乳腺癌患者中：从前瞻性，随机第3阶段3西德语学习组（WSG）Planb审判的五年数据（Vol 165，PG 573,2017）
2. Five-year results of the prospective Phase III WSG PlanB trial confirm prognostic impact of 21-Gene Recurrence Score in high-risk HR+/HER2-early breast cancer (EBC) patients with 1-3 involved lymph nodes [J] . Gluz O., Nitz U., Christgen M., The Breast : . 2017,第期

机译：前瞻性期III WSG Planb试验的五年结果确认在高风险HR + / HER2-早期乳腺癌（EBC）患者中的21-基因复发评分对1-3名涉及的淋巴结患者的预后影响
3. Prospective WSG phase III PlanB trial: Clinical outcome at 5 year follow up and impact of 21 Gene Recurrence Score result, central/local-pathological review of grade, ER, PR and Ki67 in HR+/HER2-high risk node-negative and -positive breast cancer [J] . Gluz O., Nitz U., Christgen M., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2016,第Suppla2期

机译：WSG III期PlanB的前瞻性试验：随访5年的临床结果以及21个基因复发评分结果的影响，HR // HER2高危淋巴结阴性和阳性的等级，ER，PR和Ki67的中央/局部病理学检查乳腺癌
4. Reducing chemotherapy use in clinically high-risk genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective randomised phase 3 West German Study Group (WSG) PlanB trial [O] . Ulrike Nitz, Oleg Gluz, Matthias Christgen, -1

机译：减少临床上高风险基因组低风险的pN0和pN1早期乳腺癌患者的化疗使用：前瞻性随机3期西德研究小组（WSG）PlanB试验的五年数据
5. Association of TILs with clinical parameters, Recurrence Score® results, and prognosis in patients with early HER2-negative breast cancer (BC)—a translational analysis of the prospective WSG PlanB trial [O] . Cornelia Kolberg-Liedtke, Oleg Gluz, Fred Heinisch, 2020

机译：TILs与临床参数，复发得分®结果，早期HER2阴性乳腺癌患者的预后（BC）-A转型分析，对未来的WSG PLANB试验

Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial (vol 165, pg 573, 2017)

著录项

相似文献

相关主题

期刊订阅